Date published: 2025-11-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

PDE9A Inhibitors

PDE9A inhibitors belong to a specialized chemical class distinguished by their precise molecular mechanism of action, which involves the selective targeting and inhibition of the phosphodiesterase 9A enzyme, commonly referred to as PDE9A. This enzyme holds a pivotal role in intracellular signal transduction, primarily by regulating the cyclic guanosine monophosphate (cGMP) levels within cells. By specifically binding to the active site of the PDE9A enzyme, these inhibitors impede its catalytic function, leading to a substantial increase in intracellular cGMP concentrations. This elevated cGMP concentration, in turn, impacts various downstream signaling pathways, ultimately influencing diverse cellular responses. What sets PDE9A inhibitors apart is their remarkable selectivity for the PDE9A isoform over other phosphodiesterase family members. This selectivity is pivotal, as it ensures that the modulation of cGMP signaling is highly targeted, limiting potential off-target effects. The structural design of these inhibitors is based on a deep understanding of the active site and interaction points within the PDE9A enzyme, enabling precise and effective binding.

The implications of PDE9A inhibition are far-reaching, with potential relevance in several scientific domains. Although not discussed in this context, ongoing research endeavors aim to elucidate the broader physiological roles influenced by PDE9A inhibitors. These compounds have the potential to impact cellular processes involving cGMP-dependent pathways, which extend beyond the immediate scope of their interaction with the PDE9A enzyme. Through the study of PDE9A inhibitors, scientists gain valuable insights into the intricacies of cellular signal modulation, expanding our understanding of cellular communication networks. This knowledge contributes to the advancement of basic science while also holding the promise of uncovering novel approaches for targeting specific cGMP-dependent pathways in various physiological and pathophysiological contexts.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BAY 73-6691

794568-92-6sc-252407
5 mg
$247.00
2
(0)

This is a selective PDE9A inhibitor that has been studied for its potential in cognitive deficits associated with neurodegenerative diseases.